Global Plasma Therapy Market Research and Analysis, 2015-2021
Market Insights
The market for plasma therapy across the globe is expected to propel significantly during the forecast period. According to analysts’ estimate the plasma therapy market is expected to grow impressively with a CAGR of 13.8% during 2016-2021. The factors driving the plasma therapy market are rising prevalence of life threatening diseases which includes various neurological system disorders like chronic inflammatory demyelinating polyneuropathy (CIPD), idiopathic thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN). In addition the rise in the occurrence of contagious diseases such as hepatitis A&B, tetanus and rabies is estimated to impact the market positively during the forecast period.
With an impressive technological advancement over the period has added much more to the therapies for treatment of various diseases which has also led to introduction of cost effective protein fractioning technologies from plasma. This is also being seen as a major booster to the growth within the plasma therapy market during the forecast period. As per estimates by WHO about 108 million global blood donations come from the high income countries, which is the home for 18% of the world’s population. Presence of favorable government initiates for the development of plasma derived medicine and rising awareness regarding the importance of blood donation are the key drivers for this market.
GEOGRAPHICAL INSIGHTS
On the geographical forefront, North America is a leader held the market share in 2014 which is expected to sustain during the forecast period as well. This is mainly due to the growing number of hospitals and clinics which is increasing the demand for the plasma derived from proteins. They key driving forces expected to boost the market of plasma therapy in North America are rising awareness levels among the blood donors, presence of advanced protein fractioning procedures, and higher per capita income in the developed countries.
Furthermore, APAC region is also considered to be fastest growing region mainly due to growing medical tourism, technological advancement, rising disposable income of the patients, rising healthcare practitioners awareness, and increasing government initiatives pertaining to the development of plasma protein medicines are expected to fuel the demand of plasma protein products.
The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, patent analysis, strategic recommendations, key company analysis, gap analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.
COMPETITIVE INSIGHTS
Key players of plasma therapy market include CSL limited, Telecris, Baxter, Grifols, Octapharma, Kedrion, and Chengdu Inst. Many not-for-profit organizations such as Japan Red Cross, LFB group (France), Shanghai Blood Institute, BPL group (UK), and Sanquin are also playing a vital role in plasma therapy market. The growth of commercial companies may be hampered by the not-for-profit organizations but the current demand supply gap in the market provides great scope for the new entrants during the forecast period.
OMR report covers:
The market for plasma therapy across the globe is expected to propel significantly during the forecast period. According to analysts’ estimate the plasma therapy market is expected to grow impressively with a CAGR of 13.8% during 2016-2021. The factors driving the plasma therapy market are rising prevalence of life threatening diseases which includes various neurological system disorders like chronic inflammatory demyelinating polyneuropathy (CIPD), idiopathic thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN). In addition the rise in the occurrence of contagious diseases such as hepatitis A&B, tetanus and rabies is estimated to impact the market positively during the forecast period.
With an impressive technological advancement over the period has added much more to the therapies for treatment of various diseases which has also led to introduction of cost effective protein fractioning technologies from plasma. This is also being seen as a major booster to the growth within the plasma therapy market during the forecast period. As per estimates by WHO about 108 million global blood donations come from the high income countries, which is the home for 18% of the world’s population. Presence of favorable government initiates for the development of plasma derived medicine and rising awareness regarding the importance of blood donation are the key drivers for this market.
GEOGRAPHICAL INSIGHTS
On the geographical forefront, North America is a leader held the market share in 2014 which is expected to sustain during the forecast period as well. This is mainly due to the growing number of hospitals and clinics which is increasing the demand for the plasma derived from proteins. They key driving forces expected to boost the market of plasma therapy in North America are rising awareness levels among the blood donors, presence of advanced protein fractioning procedures, and higher per capita income in the developed countries.
Furthermore, APAC region is also considered to be fastest growing region mainly due to growing medical tourism, technological advancement, rising disposable income of the patients, rising healthcare practitioners awareness, and increasing government initiatives pertaining to the development of plasma protein medicines are expected to fuel the demand of plasma protein products.
The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, patent analysis, strategic recommendations, key company analysis, gap analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.
COMPETITIVE INSIGHTS
Key players of plasma therapy market include CSL limited, Telecris, Baxter, Grifols, Octapharma, Kedrion, and Chengdu Inst. Many not-for-profit organizations such as Japan Red Cross, LFB group (France), Shanghai Blood Institute, BPL group (UK), and Sanquin are also playing a vital role in plasma therapy market. The growth of commercial companies may be hampered by the not-for-profit organizations but the current demand supply gap in the market provides great scope for the new entrants during the forecast period.
OMR report covers:
- Comprehensive research methodology of global plasma therapy market
- In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global plasma therapy market
- Insights about market determinants which are stimulating the global plasma therapy market
- Detailed and extensive market segments with regional distribution of forecasted revenues
- Extensive profiles and recent developments of market players
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.3.1. RAW MATERIAL SUPPLIERS
1.2.3.2. MANUFACTURERS
1.2.3.3. DISTRIBUTORS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
2.4. PATENT ANALYSIS
2.4.1.1. US PATENTS PUBLISHED RELATED TO PLASMA THERAPY (2014-2016)
2.4.1.2. EUROPEAN PATENTS PUBLISHED RELATED TO PLASMA THERAPY (2014-2016)
2.4.1.3. APAC PATENTS PUBLISHED RELATED TO PLASMA THERAPY (2014-2016)
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. GROWING NUMBER OF NEUROLOGICAL PATIENTS GLOBALLY
3.1.2. RISING DISPOSABLE INCOME IN THE DEVELOPING COUNTRIES
3.1.3. RISING CASES OF ARTHIRITIS GLOBALLY
3.1.4. COHESIVE GOVERNMENT INITIATIVES
3.2. RESTRAINTS
3.2.1. HIGH COST OF PLASMA THERAPY
3.2.2. LACK OF AWARNESS AMONG MASSES
3.2.3. LACK OF REIMBURSEMENT POLICIES
3.3. OPPORTUNITIES
3.3.1. RISING CASES ORTHOPAEDIC AND NEUROLOGICAL CASES
3.3.2. GROWING APPLICATION IN VARIOUS FIELDS
3.3.3. GROWING MEDICAL TOURISM IN EMERGING COUNTRIES
3.3.4. CHALLENGES
3.3.5. DEVELOPMENTS IN OTHER FIELDS OF REGENERATIVE MEDICINE
3.3.6. RESTRICTED USE OF PRP FOR DIABETIC AND KIDNEY PATIENTS
4. MARKET SEGMENTATION
4.1. PLASMA THERAPY BY SOURCE
4.1.1. AUTOLOGOUS
4.1.2. ALLOGENIC
4.2. PLASMA THERAPY BY APPLICATION
4.2.1. ORTHOPAEDICS
4.2.1.1. ARTHIRITIS
4.2.1.2. BONE REPAIR AND REGENERATION
4.2.1.3. CHRONIC TENDINITIS
4.2.2. CARDIAC MUSCLE INJURY
4.2.3. DERMATOLOGY
4.2.3.1. ANDROGENIC ALOPECIA
4.2.3.2. PLASTIC SURGERY
4.2.4. DENTAL
4.2.5. NERVE INJURY
4.2.6. OTHER APPLICATIONS
4.3. PLASMA THERAPY BY TYPE
4.3.1. LEUKOCYTE-RICH FIBRIN
4.3.2. PURE PLATELET-RICH FIBRIN
4.3.3. LEUKOCYTE-RICH PRP
4.3.4. PURE PRP
4.4. PLASMA THERAPY BY END USERS
4.4.1. HOSPITALS AND CLINICS
4.4.2. RESEARCH INSTITUTES
4.4.3. OTHERS
5. PRICING ANALYSIS
5.1. PRICING ANALYSIS (BY SIZE, EQUIPMENT AND SUPLLIES)
6. COMPETITIVE LANDSCAPE
6.1. KEY COMPANY ANALYSIS
6.2. KEY STRATEGIES
7. REGIONAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. ITALY
7.2.5. SPAIN
7.2.6. REST OF THE EUROPE
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. REST OF THE ASIA PACIFIC
7.4. REST OF THE WORLD
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.3.1. RAW MATERIAL SUPPLIERS
1.2.3.2. MANUFACTURERS
1.2.3.3. DISTRIBUTORS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
2.4. PATENT ANALYSIS
2.4.1.1. US PATENTS PUBLISHED RELATED TO PLASMA THERAPY (2014-2016)
2.4.1.2. EUROPEAN PATENTS PUBLISHED RELATED TO PLASMA THERAPY (2014-2016)
2.4.1.3. APAC PATENTS PUBLISHED RELATED TO PLASMA THERAPY (2014-2016)
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. GROWING NUMBER OF NEUROLOGICAL PATIENTS GLOBALLY
3.1.2. RISING DISPOSABLE INCOME IN THE DEVELOPING COUNTRIES
3.1.3. RISING CASES OF ARTHIRITIS GLOBALLY
3.1.4. COHESIVE GOVERNMENT INITIATIVES
3.2. RESTRAINTS
3.2.1. HIGH COST OF PLASMA THERAPY
3.2.2. LACK OF AWARNESS AMONG MASSES
3.2.3. LACK OF REIMBURSEMENT POLICIES
3.3. OPPORTUNITIES
3.3.1. RISING CASES ORTHOPAEDIC AND NEUROLOGICAL CASES
3.3.2. GROWING APPLICATION IN VARIOUS FIELDS
3.3.3. GROWING MEDICAL TOURISM IN EMERGING COUNTRIES
3.3.4. CHALLENGES
3.3.5. DEVELOPMENTS IN OTHER FIELDS OF REGENERATIVE MEDICINE
3.3.6. RESTRICTED USE OF PRP FOR DIABETIC AND KIDNEY PATIENTS
4. MARKET SEGMENTATION
4.1. PLASMA THERAPY BY SOURCE
4.1.1. AUTOLOGOUS
4.1.2. ALLOGENIC
4.2. PLASMA THERAPY BY APPLICATION
4.2.1. ORTHOPAEDICS
4.2.1.1. ARTHIRITIS
4.2.1.2. BONE REPAIR AND REGENERATION
4.2.1.3. CHRONIC TENDINITIS
4.2.2. CARDIAC MUSCLE INJURY
4.2.3. DERMATOLOGY
4.2.3.1. ANDROGENIC ALOPECIA
4.2.3.2. PLASTIC SURGERY
4.2.4. DENTAL
4.2.5. NERVE INJURY
4.2.6. OTHER APPLICATIONS
4.3. PLASMA THERAPY BY TYPE
4.3.1. LEUKOCYTE-RICH FIBRIN
4.3.2. PURE PLATELET-RICH FIBRIN
4.3.3. LEUKOCYTE-RICH PRP
4.3.4. PURE PRP
4.4. PLASMA THERAPY BY END USERS
4.4.1. HOSPITALS AND CLINICS
4.4.2. RESEARCH INSTITUTES
4.4.3. OTHERS
5. PRICING ANALYSIS
5.1. PRICING ANALYSIS (BY SIZE, EQUIPMENT AND SUPLLIES)
6. COMPETITIVE LANDSCAPE
6.1. KEY COMPANY ANALYSIS
6.2. KEY STRATEGIES
7. REGIONAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. ITALY
7.2.5. SPAIN
7.2.6. REST OF THE EUROPE
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. REST OF THE ASIA PACIFIC
7.4. REST OF THE WORLD
LIST OF TABLES
TABLE # 1 GLOBAL PLASMA THERAPY BY SOURCE MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 2 GLOBAL AUTOLOGOUS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 3 GLOBAL ALLOGENIC MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 4 GLOBAL PLASMA THERAPY BY APPLICATION 2015-2021 ($ MILLION)
TABLE # 5 GLOBAL ORTHOPAEDIC MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 6 GLOBAL ARTHIRITIS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 7 GLOBAL BONE REPAIR AND REGENERATION MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 8 GLOBAL CHRONIC TENDINITIS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 9 GLOBAL CARDIAC MUSCLE INJURY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 10 GLOBAL DERMATOLOGY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 11 GLOBAL ANDROGENIC ALOPECIA MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 12 GLOBAL PLASTIC SURGERY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 13 GLOBAL DENTAL MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 14 GLOBAL NERVE INJURY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 15 GLOBAL OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 16 GLOBAL PLASMA THERAPY BY END USERS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 17 GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 18 GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 19 GLOBAL OTHER END USERS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 20 GLOBAL PLASMA THERAPY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 21 GLOBAL LEUKOCYTE-RICH FIBRIN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 22 GLOBAL PURE PLATELET-RICH FIBRIN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 23 GLOBAL LEUKOCYTE-RICH PRP MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 24 GLOBAL PURE PRP MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 25 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 26 UNITED STATES MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 27 CANADA MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 28 EUROPEAN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 29 UNITED KINGDOM MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 30 FRANCE MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 31 GERMANY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 32 ITALY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 33 SPAIN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 34 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 35 INDIA MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 36 CHINA MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 37 JAPAN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 38 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 39 BIOLIFE PLASMA SERVICESPRODUCT PORTFOLIO
TABLE # 40 BIOLIFE PLASMA SERVICESRECENT ACTIVITIES
TABLE # 41 BIOLIFE PLASMA SERVICESSWOT ANALYSIS
TABLE # 42 BIOTESTPRODUCT PORTFOLIO
TABLE # 43 BIOTESTRECENT ACTIVITIES
TABLE # 44 BIOTESTSWOT ANALYSIS
TABLE # 45 BIO PRODUCT LABORATORY LTD. (BPL) PRODUCT PORTFOLIO
TABLE # 46 BIO PRODUCT LABORATORY LTD. (BPL) RECENT ACTIVITIES
TABLE # 47 BIO PRODUCT LABORATORY LTD. (BPL) SWOT ANALYSIS
TABLE # 48 CAMBRYN BIOLOGICS LLCPRODUCT PORTFOLIO
TABLE # 49 CAMBRYN BIOLOGICS LLCRECENT ACTIVITIES
TABLE # 50 CAMBRYN BIOLOGICS LLCSWOT ANALYSIS
TABLE # 51 CSL LTD.PRODUCT PORTFOLIO
TABLE # 52 CSL LTD.RECENT ACTIVITIES
TABLE # 53 CSL LTD.SWOT ANALYSIS
TABLE # 54 CHINA BIOLOGIC PRODUCTS, INC. PRODUCT PORTFOLIO
TABLE # 55 CHINA BIOLOGIC PRODUCTS, INC. RECENT ACTIVITIES
TABLE # 56 CHINA BIOLOGIC PRODUCTS, INC. SWOT ANALYSIS
TABLE # 57 GRIFOLS INTERNATIONAL S.A. PRODUCT PORTFOLIO
TABLE # 58 GRIFOLS INTERNATIONAL S.A. RECENT ACTIVITIES
TABLE # 59 GRIFOLS INTERNATIONAL S.A. SWOT ANALYSIS
TABLE # 60 KEDRION S.P.A. PRODUCT PORTFOLIO
TABLE # 61 KEDRION S.P.A. RECENT ACTIVITIES
TABLE # 62 KEDRION S.P.A. SWOT ANALYSIS
TABLE # 63 LFB SA PRODUCT PORTFOLIO
TABLE # 64 LFB SA RECENT ACTIVITIES
TABLE # 65 LFB SA SWOT ANALYSIS
TABLE # 66 OCTAPHARMAPRODUCT PORTFOLIO
TABLE # 67 OCTAPHARMARECENT ACTIVITIES
TABLE # 68 OCTAPHARMASWOT ANALYSIS
TABLE # 69 GE HEALTHCAREPRODUCT PORTFOLIO
TABLE # 70 GE HEALTHCARERECENT ACTIVITIES
TABLE # 71 GE HEALTHCARESWOT ANALYSIS
TABLE # 72 ANTHREXPRODUCT PORTFOLIO
TABLE # 73 ANTHREXRECENT ACTIVITIES
TABLE # 74 ANTHREXSWOT ANALYSIS
TABLE # 75 REGEN LABPRODUCT PORTFOLIO
TABLE # 76 REGEN LABRECENT ACTIVITIES
TABLE # 77 REGEN LABSWOT ANALYSIS
TABLE # 78 TRI-STAR TECHNOLOGIES PRODUCT PORTFOLIO
TABLE # 79 TRI-STAR TECHNOLOGIES RECENT ACTIVITIES
TABLE # 80 TRI-STAR TECHNOLOGIES SWOT ANALYSIS
TABLE # 1 GLOBAL PLASMA THERAPY BY SOURCE MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 2 GLOBAL AUTOLOGOUS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 3 GLOBAL ALLOGENIC MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 4 GLOBAL PLASMA THERAPY BY APPLICATION 2015-2021 ($ MILLION)
TABLE # 5 GLOBAL ORTHOPAEDIC MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 6 GLOBAL ARTHIRITIS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 7 GLOBAL BONE REPAIR AND REGENERATION MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 8 GLOBAL CHRONIC TENDINITIS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 9 GLOBAL CARDIAC MUSCLE INJURY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 10 GLOBAL DERMATOLOGY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 11 GLOBAL ANDROGENIC ALOPECIA MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 12 GLOBAL PLASTIC SURGERY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 13 GLOBAL DENTAL MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 14 GLOBAL NERVE INJURY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 15 GLOBAL OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 16 GLOBAL PLASMA THERAPY BY END USERS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 17 GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 18 GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 19 GLOBAL OTHER END USERS MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 20 GLOBAL PLASMA THERAPY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 21 GLOBAL LEUKOCYTE-RICH FIBRIN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 22 GLOBAL PURE PLATELET-RICH FIBRIN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 23 GLOBAL LEUKOCYTE-RICH PRP MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 24 GLOBAL PURE PRP MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 25 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 26 UNITED STATES MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 27 CANADA MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 28 EUROPEAN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 29 UNITED KINGDOM MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 30 FRANCE MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 31 GERMANY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 32 ITALY MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 33 SPAIN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 34 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 35 INDIA MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 36 CHINA MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 37 JAPAN MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 38 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS 2015-2021 ($ MILLION)
TABLE # 39 BIOLIFE PLASMA SERVICESPRODUCT PORTFOLIO
TABLE # 40 BIOLIFE PLASMA SERVICESRECENT ACTIVITIES
TABLE # 41 BIOLIFE PLASMA SERVICESSWOT ANALYSIS
TABLE # 42 BIOTESTPRODUCT PORTFOLIO
TABLE # 43 BIOTESTRECENT ACTIVITIES
TABLE # 44 BIOTESTSWOT ANALYSIS
TABLE # 45 BIO PRODUCT LABORATORY LTD. (BPL) PRODUCT PORTFOLIO
TABLE # 46 BIO PRODUCT LABORATORY LTD. (BPL) RECENT ACTIVITIES
TABLE # 47 BIO PRODUCT LABORATORY LTD. (BPL) SWOT ANALYSIS
TABLE # 48 CAMBRYN BIOLOGICS LLCPRODUCT PORTFOLIO
TABLE # 49 CAMBRYN BIOLOGICS LLCRECENT ACTIVITIES
TABLE # 50 CAMBRYN BIOLOGICS LLCSWOT ANALYSIS
TABLE # 51 CSL LTD.PRODUCT PORTFOLIO
TABLE # 52 CSL LTD.RECENT ACTIVITIES
TABLE # 53 CSL LTD.SWOT ANALYSIS
TABLE # 54 CHINA BIOLOGIC PRODUCTS, INC. PRODUCT PORTFOLIO
TABLE # 55 CHINA BIOLOGIC PRODUCTS, INC. RECENT ACTIVITIES
TABLE # 56 CHINA BIOLOGIC PRODUCTS, INC. SWOT ANALYSIS
TABLE # 57 GRIFOLS INTERNATIONAL S.A. PRODUCT PORTFOLIO
TABLE # 58 GRIFOLS INTERNATIONAL S.A. RECENT ACTIVITIES
TABLE # 59 GRIFOLS INTERNATIONAL S.A. SWOT ANALYSIS
TABLE # 60 KEDRION S.P.A. PRODUCT PORTFOLIO
TABLE # 61 KEDRION S.P.A. RECENT ACTIVITIES
TABLE # 62 KEDRION S.P.A. SWOT ANALYSIS
TABLE # 63 LFB SA PRODUCT PORTFOLIO
TABLE # 64 LFB SA RECENT ACTIVITIES
TABLE # 65 LFB SA SWOT ANALYSIS
TABLE # 66 OCTAPHARMAPRODUCT PORTFOLIO
TABLE # 67 OCTAPHARMARECENT ACTIVITIES
TABLE # 68 OCTAPHARMASWOT ANALYSIS
TABLE # 69 GE HEALTHCAREPRODUCT PORTFOLIO
TABLE # 70 GE HEALTHCARERECENT ACTIVITIES
TABLE # 71 GE HEALTHCARESWOT ANALYSIS
TABLE # 72 ANTHREXPRODUCT PORTFOLIO
TABLE # 73 ANTHREXRECENT ACTIVITIES
TABLE # 74 ANTHREXSWOT ANALYSIS
TABLE # 75 REGEN LABPRODUCT PORTFOLIO
TABLE # 76 REGEN LABRECENT ACTIVITIES
TABLE # 77 REGEN LABSWOT ANALYSIS
TABLE # 78 TRI-STAR TECHNOLOGIES PRODUCT PORTFOLIO
TABLE # 79 TRI-STAR TECHNOLOGIES RECENT ACTIVITIES
TABLE # 80 TRI-STAR TECHNOLOGIES SWOT ANALYSIS
LIST OF FIGURES
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 5 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 6 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 7 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 8 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 9 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 10 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2021
COMPANIES MENTIONED
8. COMPANY PROFILES
8.1. BIOLIFE PLASMA SERVICES
8.1.1. INTRODUCTION
8.1.2. BIOLIFE PLASMA SERVICESPRODUCT PORTFOLIO
8.1.3. BIOLIFE PLASMA SERVICESRECENT ACTIVITIES
8.1.4. BIOLIFE PLASMA SERVICESSWOT ANALYSIS
8.2. BIOTEST
8.2.1. INTRODUCTION
8.2.2. BIOTESTPRODUCT PORTFOLIO
8.2.3. BIOTESTRECENT ACTIVITIES
8.2.4. BIOTESTSWOT ANALYSIS
8.3. BIO PRODUCT LABORATORY LTD. (BPL)
8.3.1. INTRODUCTION
8.3.2. BIO PRODUCT LABORATORY LTD. (BPL) PRODUCT PORTFOLIO
8.3.3. BIO PRODUCT LABORATORY LTD. (BPL) RECENT ACTIVITIES
8.3.4. BIO PRODUCT LABORATORY LTD. (BPL) SWOT ANALYSIS
8.4. CAMBRYN BIOLOGICS LLC
8.4.1. INTRODUCTION
8.4.2. CAMBRYN BIOLOGICS LLCPRODUCT PORTFOLIO
8.4.3. CAMBRYN BIOLOGICS LLCRECENT ACTIVITIES
8.4.4. CAMBRYN BIOLOGICS LLCSWOT ANALYSIS
8.5. CSL LTD.
8.5.1. INTRODUCTION
8.5.2. CSL LTD.PRODUCT PORTFOLIO
8.5.3. CSL LTD.RECENT ACTIVITIES
8.5.4. CSL LTD.SWOT ANALYSIS
8.6. CHINA BIOLOGIC PRODUCTS, INC.
8.6.1. INTRODUCTION
8.6.2. CHINA BIOLOGIC PRODUCTS, INC. PRODUCT PORTFOLIO
8.6.3. CHINA BIOLOGIC PRODUCTS, INC. RECENT ACTIVITIES
8.6.4. CHINA BIOLOGIC PRODUCTS, INC. SWOT ANALYSIS
8.7. GRIFOLS INTERNATIONAL S.A.
8.7.1. INTRODUCTION
8.7.2. GRIFOLS INTERNATIONAL S.A. PRODUCT PORTFOLIO
8.7.3. GRIFOLS INTERNATIONAL S.A. RECENT ACTIVITIES
8.7.4. GRIFOLS INTERNATIONAL S.A. SWOT ANALYSIS
8.8. KEDRION S.P.A.
8.8.1. INTRODUCTION
8.8.2. KEDRION S.P.A. PRODUCT PORTFOLIO
8.8.3. KEDRION S.P.A. RECENT ACTIVITIES
8.8.4. KEDRION S.P.A. SWOT ANALYSIS
8.9. LFB SA
8.9.1. INTRODUCTION
8.9.2. LFB SA PRODUCT PORTFOLIO
8.9.3. LFB SA RECENT ACTIVITIES
8.9.4. LFB SA SWOT ANALYSIS
8.10. OCTAPHARMA
8.10.1. INTRODUCTION
8.10.2. OCTAPHARMAPRODUCT PORTFOLIO
8.10.3. OCTAPHARMARECENT ACTIVITIES
8.10.4. OCTAPHARMASWOT ANALYSIS
8.11. GE HEALTHCARE
8.11.1. INTRODUCTION
8.11.2. GE HEALTHCAREPRODUCT PORTFOLIO
8.11.3. GE HEALTHCARERECENT ACTIVITIES
8.11.4. GE HEALTHCARESWOT ANALYSIS
8.12. ANTHREX
8.12.1. INTRODUCTION
8.12.2. ANTHREXPRODUCT PORTFOLIO
8.12.3. ANTHREXRECENT ACTIVITIES
8.12.4. ANTHREXSWOT ANALYSIS
8.13. REGEN LAB
8.13.1. INTRODUCTION
8.13.2. REGEN LABPRODUCT PORTFOLIO
8.13.3. REGEN LABRECENT ACTIVITIES
8.13.4. REGEN LABSWOT ANALYSIS
8.14. TRI-STAR TECHNOLOGIES
8.14.1. INTRODUCTION
8.14.2. TRI-STAR TECHNOLOGIES PRODUCT PORTFOLIO
8.14.3. TRI-STAR TECHNOLOGIES RECENT ACTIVITIES
8.14.4. TRI-STAR TECHNOLOGIES SWOT ANALYSIS
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 5 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 6 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 7 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 8 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 9 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2021
FIGURE # 10 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2021
COMPANIES MENTIONED
8. COMPANY PROFILES
8.1. BIOLIFE PLASMA SERVICES
8.1.1. INTRODUCTION
8.1.2. BIOLIFE PLASMA SERVICESPRODUCT PORTFOLIO
8.1.3. BIOLIFE PLASMA SERVICESRECENT ACTIVITIES
8.1.4. BIOLIFE PLASMA SERVICESSWOT ANALYSIS
8.2. BIOTEST
8.2.1. INTRODUCTION
8.2.2. BIOTESTPRODUCT PORTFOLIO
8.2.3. BIOTESTRECENT ACTIVITIES
8.2.4. BIOTESTSWOT ANALYSIS
8.3. BIO PRODUCT LABORATORY LTD. (BPL)
8.3.1. INTRODUCTION
8.3.2. BIO PRODUCT LABORATORY LTD. (BPL) PRODUCT PORTFOLIO
8.3.3. BIO PRODUCT LABORATORY LTD. (BPL) RECENT ACTIVITIES
8.3.4. BIO PRODUCT LABORATORY LTD. (BPL) SWOT ANALYSIS
8.4. CAMBRYN BIOLOGICS LLC
8.4.1. INTRODUCTION
8.4.2. CAMBRYN BIOLOGICS LLCPRODUCT PORTFOLIO
8.4.3. CAMBRYN BIOLOGICS LLCRECENT ACTIVITIES
8.4.4. CAMBRYN BIOLOGICS LLCSWOT ANALYSIS
8.5. CSL LTD.
8.5.1. INTRODUCTION
8.5.2. CSL LTD.PRODUCT PORTFOLIO
8.5.3. CSL LTD.RECENT ACTIVITIES
8.5.4. CSL LTD.SWOT ANALYSIS
8.6. CHINA BIOLOGIC PRODUCTS, INC.
8.6.1. INTRODUCTION
8.6.2. CHINA BIOLOGIC PRODUCTS, INC. PRODUCT PORTFOLIO
8.6.3. CHINA BIOLOGIC PRODUCTS, INC. RECENT ACTIVITIES
8.6.4. CHINA BIOLOGIC PRODUCTS, INC. SWOT ANALYSIS
8.7. GRIFOLS INTERNATIONAL S.A.
8.7.1. INTRODUCTION
8.7.2. GRIFOLS INTERNATIONAL S.A. PRODUCT PORTFOLIO
8.7.3. GRIFOLS INTERNATIONAL S.A. RECENT ACTIVITIES
8.7.4. GRIFOLS INTERNATIONAL S.A. SWOT ANALYSIS
8.8. KEDRION S.P.A.
8.8.1. INTRODUCTION
8.8.2. KEDRION S.P.A. PRODUCT PORTFOLIO
8.8.3. KEDRION S.P.A. RECENT ACTIVITIES
8.8.4. KEDRION S.P.A. SWOT ANALYSIS
8.9. LFB SA
8.9.1. INTRODUCTION
8.9.2. LFB SA PRODUCT PORTFOLIO
8.9.3. LFB SA RECENT ACTIVITIES
8.9.4. LFB SA SWOT ANALYSIS
8.10. OCTAPHARMA
8.10.1. INTRODUCTION
8.10.2. OCTAPHARMAPRODUCT PORTFOLIO
8.10.3. OCTAPHARMARECENT ACTIVITIES
8.10.4. OCTAPHARMASWOT ANALYSIS
8.11. GE HEALTHCARE
8.11.1. INTRODUCTION
8.11.2. GE HEALTHCAREPRODUCT PORTFOLIO
8.11.3. GE HEALTHCARERECENT ACTIVITIES
8.11.4. GE HEALTHCARESWOT ANALYSIS
8.12. ANTHREX
8.12.1. INTRODUCTION
8.12.2. ANTHREXPRODUCT PORTFOLIO
8.12.3. ANTHREXRECENT ACTIVITIES
8.12.4. ANTHREXSWOT ANALYSIS
8.13. REGEN LAB
8.13.1. INTRODUCTION
8.13.2. REGEN LABPRODUCT PORTFOLIO
8.13.3. REGEN LABRECENT ACTIVITIES
8.13.4. REGEN LABSWOT ANALYSIS
8.14. TRI-STAR TECHNOLOGIES
8.14.1. INTRODUCTION
8.14.2. TRI-STAR TECHNOLOGIES PRODUCT PORTFOLIO
8.14.3. TRI-STAR TECHNOLOGIES RECENT ACTIVITIES
8.14.4. TRI-STAR TECHNOLOGIES SWOT ANALYSIS
